MiNK Therapeutics, Inc. (INKT) and Autonomous Therapeutics, Inc. announced their research collaboration on Tuesday, with the goal of developing groundbreaking treatments for metastatic tumors. This strategic partnership aims to assess the potential of Autonomous' precision encrypted RNA technology alongside MiNK's iNKT cell therapies, namely MiNK-215 and agenT-797, within models of metastatic solid tumors. Dependent on the findings obtained, both companies intend to initiate a Phase 1 clinical trial involving patients who suffer from treatment-refractory metastatic solid tumors, including those with microsatellite stable colorectal cancers.
"The objective is to create innovative therapies that can effectively target metastatic cancer cells, all the while sparing healthy cells—a hurdle that current cancer treatments struggle to overcome," MiNK stated.
AgenT-797 is presently undergoing a Phase 2 clinical trial targeting second-line gastric cancer, whereas MiNK-215 is still in the pre-clinical stage.
